Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518698 · ClinicalTrials.gov registry record
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,163
- Enrollment target
NCT02518698: Completed study, sponsored by Bayer.
NCT02518698 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,163 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02518698 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,163 participants
- Enrollment target
Study Summary
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
Primary Outcome
mCRPC: Metastatic castrate-resistant prostate cancer
Interventions
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,163 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2017-09-30 |
What the finished NCT02518698 record still lists
NCT02518698 is an observational study that tracks outcomes without assigning an intervention. Its 1,163 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.
NCT02518698 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02518698 about?
NCT02518698 is a clinical study titled "Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population". The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
What is the current status of trial NCT02518698?
This trial is currently completed. The enrollment target is 1,163 participants. The study started on 2015-08-31. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT02518698?
The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02518698?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI